Category Archives: News

FDA places a partial hold on all venetoclax clinical trials for multiple myeloma (MM) patients

The U.S. Food and Drug Administration (FDA) put the partial hold on all MM trials when they did a pre-planned...

Venetoclax Will be Paid for in Australia

Venetoclax (Venclexta®), will be added to Australian Pharmaceutical Benefits Scheme (PBS) starting March 1, 2019. Venetoclax was developed in Australia and though...

CMS approves CAR-T therapy payment, but with significant strings attached

CMS is the the government agency that decides what gets paid for and what doesn't by Medicare and Medicaid. Often...

Bristol-Myers Squibb to Acquire Celgene

On Jan. 22, 2018, Celgene announced they had acquired Juno Therapeutics. Juno’s CAR-T, JCAR017, looks very promising in CLL and...

The FDA’s 10th approval of ibrutinib, this time in combination with obinutuzumab for frontline therapy for CLL

Today, Jan. 28., 2019, “FDA approved the use of IMBRUVICA® (ibrutinib) in combination with obinutuzumab (GAZYVA®) for adult patients with...

Duvelisib approved for Relapsed and Refractory CLL after failing 2 lines of therapy

For chronic lymphocytic leukemia patients, it is always good to have more options. The FDA’s approval of duvelisib, a very effective...

Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to Venetoclax tablet Label

Minimal residual disease (MRD)-negativity is a big deal and is now being recognized right on the label of venetoclax, a...